Automating Oncology CGM Prior Auth for Seamless Cancer Care

Navigating the complexities of **oncology CGM prior auth** is critical for timely patient care, ensuring continuous glucose monitoring is available when needed alongside demanding cancer treatments.

Revenue cycle directors and prior authorization coordinators in oncology face unique challenges, balancing urgent treatment starts with the intricate demands of prior authorization. When continuous glucose monitoring (CGM) is also required, the administrative burden can escalate, risking delays in both cancer treatment and essential diabetes management. Klivira provides a specialized solution to streamline these critical workflows.

The Dual Challenge: Oncology and CGM Prior Authorization

Oncology prior authorization is among the most demanding in healthcare, characterized by high-cost biologics, frequent regimen changes, and urgent treatment timelines. Patients undergoing cancer therapy may also require continuous glucose monitoring (CGM) for diabetes management, adding another layer of PA complexity. Efficiently managing both streams of authorization is vital to prevent care delays and reduce administrative overhead.

Key Prior Authorization Triggers in Oncology

J-code chemotherapy and biologic infusions, including immunotherapies and targeted therapies.
Advanced imaging for staging and surveillance (e.g., PET/CT, advanced MRI).
Radiation oncology procedures (IMRT, IGRT, SBRT, brachytherapy, proton-beam therapy).
Specialty oral oncolytics, often under the pharmacy benefit.
Supportive care medications like growth factors (G-CSF, ESAs) and antiemetics.

Navigating CGM Prior Authorization Requirements

Continuous glucose monitor (CGM) prior authorization typically requires documentation of diabetes type (Type 1 or Type 2) and insulin dependence. Payers often assess medical necessity based on A1C levels, frequency of self-monitoring blood glucose (SMBG), and history of hypoglycemia. Managing initial CGM authorization and subsequent supply re-authorizations efficiently is crucial for consistent patient access.

Klivira's Integrated Approach for Complex Oncology and CGM Needs

Klivira's platform is engineered to manage the intricate demands of both oncology and CGM prior authorizations. By integrating with EMRs, we surface NCCN-compendium-aware policy logic for oncology regimens and streamline documentation capture for CGM requests. Our system ensures appropriate routing for medical vs. pharmacy benefit items, a common split in oncology, extending to durable medical equipment like CGMs.

EMR Integration and Payer Connectivity for Seamless Workflows

Klivira integrates directly with major EMR systems via SMART on FHIR, enabling point-of-order PA initiation for both oncology treatments and CGM prescriptions. We connect with payer portals and utilize X12 278 transactions for medical benefit items, and ePA partners like CoverMyMeds and Surescripts for pharmacy benefit drugs and devices. This comprehensive connectivity reduces manual effort and accelerates approval cycles for all necessary services.

Frequently asked questions

How does Klivira handle the unique urgency of oncology prior authorizations?

Klivira's platform prioritizes urgent oncology PAs, automating documentation assembly and submission to accelerate approval cycles. We account for regimen-level PA requirements and the frequent changes common in cancer care, aiming to minimize delays that could impact treatment initiation and patient outcomes.

What specific documentation does Klivira help gather for CGM prior authorizations in oncology patients?

For CGM prior authorizations, Klivira helps consolidate essential documentation such as diabetes type, insulin dependence status, A1C levels, and self-monitoring frequency. This ensures that all necessary clinical criteria are met for both initial authorization and supply re-authorizations, reducing common denial reasons.

Can Klivira manage both medical and pharmacy benefit PAs for oncology patients also using CGM?

Yes, Klivira's platform intelligently routes prior authorization requests based on benefit type. This is critical for oncology, where treatments can span medical benefit (IV infusions) and pharmacy benefit (oral oncolytics), and for CGM devices which may fall under either. Our system ensures accurate submission via appropriate channels (X12 278, ePA).

How does Klivira address common denial reasons for oncology treatments and CGM?

Klivira's NCCN-compendium-aware logic helps prevent denials related to off-label use or documentation gaps in oncology. For CGM, it ensures all required clinical criteria are present. For both, our platform flags potential step therapy issues and supports efficient appeal pathways, including facilitating peer-to-peer review scheduling.

Does Klivira integrate with our existing EMR for oncology and CGM PA workflows?

Yes, Klivira offers robust integration with leading EMR systems, including SMART on FHIR capabilities. This allows for seamless data exchange, enabling prior authorization requests to be initiated directly from the EMR at the point of order entry for both oncology treatments and continuous glucose monitors.